4-chloro-6-fluoro-7-methoxyquinoline | 851985-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-chloro-6-fluoro-7-methoxyquinoline
• CAS: 851985-92-7
• 化学式: C₁₀H₇ClFNO
• 分子量: 211.623
• InChiKey: GNZAVVFCQPSILT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-6-fluoro-7-methoxyquinoline 在 盐酸 、 三乙胺 、 N,N-二异丙基乙胺 、 三苯基二氯化膦 作用下， 以 乙酸乙酯 、 正丁醇 为溶剂， 反应 36.25h， 生成 [8-(6-fluoro-7-methoxyquinolin-4-yl)-2,8-diazaspiro[4.5]decan-2-yl](imino)methyl-λ⁶-sulfanone
  参考文献：
  名称：

  [EN] IMINO SULFANONE INHIBITORS OF ENPP1
  [FR] INHIBITEURS IMINO SULFANONE DE L'ENPP1

  摘要：

  本公开涉及一般来说是对细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）的抑制剂，其组合物以及使用所述化合物和组合物的方法。更具体地说，本公开涉及基于砜亚胺的ENPP1抑制剂，其化学式为（I），以及其用于治疗由ENPP1介导的疾病的方法。

  公开号：

  WO2021225969A1
• 作为产物：
  描述：

  6-fluoro-7-methoxyquinolin-4(1H)-one 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以86.9 %的产率得到4-chloro-6-fluoro-7-methoxyquinoline
  参考文献：
  名称：

  [EN] HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF
  [FR] COMPOSÉ D'ACIDE HYDROXAMIQUE AYANT UNE ACTIVITÉ INHIBITRICE DE L'ENPP1 ET SON UTILISATION
  [ZH] 具有ENPP1抑制活性的异羟基肟酸类化合物及其用途

  摘要：

  公开具有ENPP1抑制活性的式(I)化合物、其药物组合物和用途。式(I)化合物可用于预防或治疗由ENPP1异常活性介导的那些疾病或障碍。

  公开号：

  WO2023036289A1

文献信息

• [EN] ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE-PHOSPHODIESTÉRASE (ENPP-1) ET UTILISATIONS DE CES DERNIERS
  申请人：MAVUPHARMA INC

  公开号：WO2019046778A1

  公开（公告）日：2019-03-07

  Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

  本文揭示了一种增强和促进体内I型干扰素产生的方法和化合物。在某些实施例中，本文所披露的化合物是ENPP-1抑制剂，药物组合物，以及用于治疗癌症或病毒感染的方法。
• [EN] SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN<br/>[FR] UTILISATION D'HETEROCYCLES AMINES A SIX ELEMENTS CONTENANT DE L'AZOTE SUBSTITUES COMME ANTAGONISTES DU RECEPTEUR VANILLOIDE DE TYPE 1 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：MERCK SHARP & DOHME

  公开号：WO2005047279A1

  公开（公告）日：2005-05-26

  The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1- 4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.

  本发明提供了一种化合物，其化学式为（I）：Y-J-NH-Z，其中：Y为喹啉或异喹啉，可选地取代为一个或两个从羟基、卤素、卤代C1-4烷基、C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、硝基和氨基中独立选择的取代基；J为吡啶、吡啶嗪、吡嗪、嘧啶或三嗪，可选地取代为一个或两个从羟基、卤素、卤代C1-4烷基、C1-4烷基、C3-5环烷基、C1-4烷氧基、羟基C1-4烷基、氰基、羟基、C1-4环烷氧基、C1-4烷基硫氧基、卤代C1-4烷氧基、硝基、Q、（CH2）pQ、NR2R3、-（CH2）pNR2R3和-O（CH2）pNR2R3中独立选择的取代基；其中J在相对于NH和Y的位置上被取代；Z为苯基或吡啶基，可选地取代为一个或两个从卤素、卤代C1-4烷基、C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、硝基和氨基中独立选择的取代基；Q为苯基，含有一个、两个、三个或四个从O、N和S中选择的杂原子的五元杂环，最多一个杂原子为O或S，或含有一个、两个或三个氮原子的六元杂环，可选地取代为C1-4烷基；每个R2和R3从H和C1-4烷基中选择，或R2和R3，连同它们连接的氮原子，可形成一个含有氧原子或进一步氮原子的六元环，该环可选地取代为C1-4烷基或Q；p为1、2或3；或其药学上可接受的盐；包含它的药物组合物；其在治疗方法中的使用；用于制造药物的使用；以及使用它治疗需要VR1拮抗剂（如疼痛、咳嗽、胃食管反流病和抑郁症）的疾病的方法。
• OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Wellmarker Bio Co., Ltd.

  公开号：EP4011885A1

  公开（公告）日：2022-06-15

  An oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines. Therefore, the oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention can be advantageously used for preventing or treating a disease associated with protein kinase activity.

  根据本发明，化学式1所代表的一种氧代吡啶融合环衍生物化合物或其药学上可接受的盐，可以有效抑制RON的活性，不仅可以有效抑制RON被激活的癌细胞系的细胞生长，还可以有效杀死癌细胞系。因此，根据本发明，化学式1所代表的氧代吡啶融合环衍生物化合物或其药学上可接受的盐可以有利地用于预防或治疗与蛋白激酶活性相关的疾病。
• Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
  申请人：Hollingworth John Gregory

  公开号：US20050197342A1

  公开（公告）日：2005-09-08

  The present invention provides a compound of formula I: Y-J-NH-Z  (I) wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC 1-4 alkyl, C 1-4 alkyl, C 3-5 cycloalkyl, C 1-4 alkoxy, hydroxyC 1-4 alkyl, cyano, hydroxy, C 1-4 cycloalkoxy, C 1-4 alkylthio, haloC 1-4 alkoxy, nitro, Q, (CH 2 ) p Q, —NR 2 R 3 , —(CH 2 ) p NR 2 R 3 and —O(CH 2 ) p NR 2 R 3 ; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C 1-4 alkyl; each R 2 and R 3 is chosen from H and C 1-4 alkyl, or R 2 and R 3 , together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C 1-4 alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.

  本发明提供一种公式I的化合物：Y-J-NH-Z（I），其中：Y是喹啉或异喹啉，可选地取代一个或两个取代基，独立地选择自羟基，卤素，卤基C1-4烷基，C1-4烷基，C1-4烷氧基，卤基C1-4烷氧基，硝基和氨基；J是吡啶，吡嗪，吡咯，嘧啶或三嗪，可选地取代一个或两个取代基，独立地选择自羟基，卤素，卤基C1-4烷基，C1-4烷基，C3-5环烷基，C1-4烷氧基，羟基C1-4烷基，氰基，C1-4环烷氧基，C1-4烷基硫基，卤基C1-4烷氧基，硝基，Q，（CH2）pQ，—NR2R3，—（CH2）pNR2R3和—O（CH2）pNR2R3；其中J在与Y相对的位置上被NH取代；Z是苯基或吡啶基，可选地取代一个或两个取代基，独立地选择自卤素，卤基C1-4烷基，C1-4烷基，C1-4烷氧基，卤基C1-4烷氧基，硝基和氨基；Q是苯基，含有一个、两个、三个或四个杂原子（O、N和S）的五元杂环，最多有一个杂原子为O或S，或含有一个、两个或三个氮原子的六元杂环，可选地被C1-4烷基取代；每个R2和R3选择自H和C1-4烷基，或者R2和R3与它们连接的氮原子一起，可以形成一个六元环，可选地含有一个氧原子或进一步的氮原子，该环可选地被C1-4烷基或Q取代；p为1、2或3；或其药学上可接受的盐；包含该化合物的药物组合物；其在治疗方法中的使用；用于制造药物的使用；以及使用它治疗需要VR1拮抗剂（如疼痛、咳嗽、GERD和抑郁症）的疾病的方法。
• COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1724268A1

  公开（公告）日：2006-11-22

  The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGFβ inhibitory activity.

  本发明提供了式(I)化合物或式(II)化合物及其药学上可接受的盐或溶液。本发明的目的是提供具有 TGFβ 抑制活性的化合物。